Live
Endpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3BFierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownBioPharma DiveInnovation alone is no longer enough in biopharmaBioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalabilityRoche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.comFierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical developmentFierceBiotechManaging complexity across biopharma modalitieseLifeCharacterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activityeLifeA macroevolution-inspired approach to reveal novel antibiotic resistance mechanismseLifeA comprehensive mechanosensory connectome reveals a somatotopically organized neural circuit architecture controlling stimulus-aimed grooming of the <i>Drosophila</i> head
Endpoints News 21. Jan. 2026

IntraBio says rare disease drug passes Phase 3, will seek FDA approval

IntraBio says rare disease drug passes Phase 3, will seek FDA approval

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.